1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Postpartum Depression- Market Insight, Epidemiology and Market Forecast -2030

Postpartum Depression- Market Insight, Epidemiology and Market Forecast -2030

  • April 2020
  • 200 pages
  • ID: 5885409
  • Format: PDF
  • Delve Insight


Table of Contents

‘Postpartum Depression (PPD) -Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Postpartum Depression (PPD), historical and forecasted epidemiology as well as the Postpartum Depression (PPD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Postpartum Depression (PPD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Postpartum Depression (PPD) market size from 2017 to 2030. The report also covers current Postpartum Depression (PPD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Postpartum Depression (PPD) Disease Understanding and Treatment Algorithm

Postpartum Depression (PPD) Overview
Postpartum depression (PPD) is the most common non-psychotic, complication of childbearing affecting approximately 10–15% of women and as such, represents a considerable public health problem affecting women and their families. The postnatal period is well established as an increased time of risk for the development of serious mood disorders. There are three common forms of postpartum affective illness: the blues (baby blues, maternity blues), postpartum (or postnatal) depression, and puerperal (postpartum or postnatal) psychosis each of which differs in its prevalence, clinical presentation, and management.
Postpartum depression usually begins within 1–12 months after delivery. In some women, post-partum blues simply continue and become more severe. In others, a period of wellbeing after delivery is followed by a gradual onset of depression. The patterns of symptoms in women with postpartum depression are similar to those in women who have depression unrelated to childbirth. Several factors can lead to postpartum depression. Women with a history of depression and other mental health conditions face a higher risk of PPD.

Postpartum Depression (PPD) Diagnosis
Women who are at risk for postpartum depression should be identified as soon as possible during pregnancy so that appropriate follow-up and care can be initiated. Risk factors for postpartum depression include depression, anxiety, stressful life events during pregnancy or the early puerperium, low levels of social support, and a personal or family history of depression. Women with a history of postpartum depression are also at increased risk of recurrence.
Screening for postpartum depression should be considered strongly, although evidence in support of universal screening tools is lacking. Patients with known risk factors may be selected for screening with the EPDS. The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-rated instrument that has been used widely to screen for postpartum depression. A reasonable cut-off on the EPDS is a score of 13 or greater, even though the sensitivity and specificity vary across languages and cultures. Patients with a score of 13 or greater should be assessed for depression; however, a special note should be made of positive responses on item 10 regarding suicidal ideation.

Postpartum Depression (PPD) Treatment
Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in the treatment of PPD. Other treatments, which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary.
As in the case of other types of depression, PPD can be treated using a combination of therapy and antidepressant medications. There are other classes of medications which are being prescribed for PPD as off-label therapies. One such class of medication is known as selective serotonin reuptake inhibitors (SSRIs), which includes fluoxetine and sertraline. SSRIs relieve symptoms by blocking the reabsorption, or reuptake, of serotonin by specific nerve cells in the brain; this increases the level of available serotonin, which improves the mood of the patient. SSRIs (citalopram, escitalopram, fluoxetine, paroxetine, and sertraline) are generally found to produce fewer side effects when compared with tricyclic antidepressants. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) has also been found useful in the treatment of PPD.
It covers the details of conventional and current medical therapies available in the PPD market for the treatment of the various types of PPD. It also provides the treatment guidelines and algorithms of the United States and Europe. The ’s Postpartum Depression (PPD) market report gives a thorough understanding of Postpartum Depression (PPD) by including details such as disease introduction, causes, risk factors, pathogenesis, and diagnosis.

Postpartum Depression (PPD) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Maternal Postpartum Depression and Type-specific Diagnosed Prevalence of Postpartum Depression scenario of Postpartum Depression (PPD) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings
This section provides glimpse of the Postpartum Depression (PPD) epidemiology in the 7MM.
• In the 7MM, the total diagnosed prevalent cases of PPD in 2017 were 1,134,800 out of which the highest diagnosed prevalent cases of this disease were seen in the United States, which were 609,900, which is expected to increase during forecast period (2020–2030).
• As per the estimates, in Japan the diagnosed prevalence of PPD was found to be the second highest after the US with 116,280 in 2017.

Country Wise- Postpartum Depression (PPD) Epidemiology
The epidemiology segment also provides the Postpartum Depression (PPD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Postpartum Depression (PPD) Drug Chapters
The drug chapter segment of the PPD report encloses the detailed analysis of PPD marketed drugs and mid and late stage pipeline drugs. It also helps to understand the PPD clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Postpartum Depression (PPD) Marketed Drugs
Zulresso (brexanolone): Sage Therapeutics
Zulresso marketed by Sage Therapeutics is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adults. Brexanolone was granted a priority review and was designated a breakthrough treatment by the FDA. Brexanolone is available to the patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. It is important to note that Zulresso (brexanolone) is the first drug approved by the US FDA specifically for postpartum depression in adults. Zulresso has also been granted PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for the treatment of PPD.
Product detail in the report…

Postpartum Depression (PPD) Emerging Drugs
Zuranolone (SAGE-217): Sage Therapeutics
Zuranolone (SAGE-217) by Sage Therapeutics is an investigational, oral, novel medicine in development for postpartum depression. It is given once-daily; a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), which contributes in regulating CNS function significantly.
Product detail in the report…
Ganaxolone (CCD-1042): Marinus Pharmaceuticals
Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited antiepileptic (anti-seizure), anxiolytic (anti-anxiety), and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (intravenous, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits anti-seizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors.
Product detail in the report…

Postpartum Depression (PPD) Market Outlook
According to the American Psychiatric Association (APA), Postpartum depression (PPD) is a serious, but treatable medical illness, which involves feelings of extreme sadness, emotional liability, indifference and/or anxiety, as well as changes in energy, sleep, and appetite, and carries risks for the mother and the newborn child. PPD usually starts within the first month or any time within the first year after childbirth and can last from weeks to months. In more severe cases, it can develop into chronic episodes of depression.
Treatments include the antidepressant medications along with the new upcoming therapeutic strategies that work on the principle of GABAA receptor modulation. The medical management for PPD comprises several aspects such as interventions for depression, anxiety disorders, alcohol and drug abuse, and psychological interventions for eating disorders. The treatment strategy also encompasses psychological and psychosocial treatments, as well as non-pharmacologic treatments. Besides, the medical care of a PDD patient and his family is incomplete without providing a support system for their psychosocial wellbeing. The current US market consists of only one approved product—Zulresso (brexanolone/SAGE-547)—to treat patients with PPD. Zulresso, which is marketed by Sage Therapeutics, was approved by the US FDA, in March 2019.
The PPD market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted PPD market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of PPD market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the report, PPD 7MM market is expected to change in the study period 2017–2030.

Key Findings
This section includes a glimpse of the Postpartum Depression (PPD) 7MM market.
• The United States accounts for the largest market size of Postpartum Depression (PPD), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
• The market size of Postpartum Depression (PPD) in the seven major markets is USD 138.75 Million in 2017 for the study period (2017–2030).

The United States Market Outlook
This section provides the total Postpartum Depression (PPD) market size and market size by therapies in the United States.

EU-5 Market Outlook
The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook
The total Postpartum Depression (PPD) market size and market size by therapies in Japan are provided.

Postpartum Depression (PPD) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Postpartum Depression (PPD) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Postpartum Depression (PPD) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Postpartum Depression (PPD) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Postpartum Depression (PPD) emerging therapies.

Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Postpartum Depression (PPD) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of Postpartum Depression (PPD), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the Postpartum Depression (PPD) epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Postpartum Depression (PPD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Postpartum Depression (PPD) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Postpartum Depression (PPD) market.

Report Highlights
• In the coming years, Postpartum Depression (PPD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Postpartum Depression (PPD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players such as Sage Therapeutics and Marinus Pharmaceuticals are involved in developing therapies for Postpartum Depression (PPD). Launch of emerging therapies such as SAGE-217 and Ganaxolone will significantly impact the Postpartum Depression (PPD) market. Out of the two prominent emerging players Sage Therapeutics is a leading player and its potential drug SAGE-217 has shown promising results in the clinical trials for PPD.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Postpartum Depression (PPD) Report Insights
• Patient Population
• Therapeutic Approaches
• Postpartum Depression (PPD) Pipeline Analysis
• Postpartum Depression (PPD) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Postpartum Depression (PPD) Report Key Strengths
• Eleven Years Forecast
• 7MM Coverage
• Postpartum Depression (PPD) Epidemiology Segmentation (Maternal as well as paternal PPD)
• Type-specific Diagnosed Prevalence of PPD (Postpartum blues, Obsessive Compulsive Disorder post-pregnancy, Postpartum Psychosis, Posttraumatic stress disorder (PTSD) and Postpartum Panic Disorder)
• Key Cross Competition
• Highly Analyzed Market

• Drugs Uptake

Postpartum Depression (PPD) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:
• What was the Postpartum Depression (PPD) market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Postpartum Depression (PPD) total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Postpartum Depression (PPD) market size during the forecast period (2020–2030)?
• At what CAGR, the Postpartum Depression (PPD) market is expected to grow at the 7MM level during the forecast period (2020–2030)?
• What would be the Postpartum Depression (PPD) market outlook across the 7MM during the forecast period (2020–2030)?
• What would be the Postpartum Depression (PPD) market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What is the disease risk, burden and unmet needs of Postpartum Depression (PPD)?
• What is the historical Postpartum Depression (PPD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Postpartum Depression (PPD) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Postpartum Depression (PPD)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Postpartum Depression (PPD) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
• What are the current options for the treatment of Postpartum Depression (PPD) along with the approved therapy?
• What are the current treatment guidelines for the treatment of Postpartum Depression (PPD) in the US and Europe?
• What are the Postpartum Depression (PPD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Postpartum Depression (PPD)?
• How many therapies are developed by each company for the treatment of Postpartum Depression (PPD)?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Postpartum Depression (PPD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postpartum Depression (PPD) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postpartum Depression (PPD) and their status?
• What are the key designations that have been granted for the emerging therapies for Postpartum Depression (PPD)?
• What are the 7MM historical and forecasted market of Postpartum Depression (PPD)?

Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Postpartum Depression (PPD).
- To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Postpartum Depression (PPD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for Postpartum Depression (PPD) market.
- To understand the future market competition in the Postpartum Depression (PPD) market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on